Filing Flows › Evolent Health (EVH) › Q3 2026 › vs Q3 2025
Evolent Health (EVH) Q3 2026 vs Q3 2025 (year over year)
Evolent Health's revenue rose $246M (+51%) from $480M in Q3 2025 to $725M in Q3 2026.
Evolent Health, Q3 2026: revenue $725M (+51% year over year), operating margin -0.9%, net loss $23.6M, operating cash flow $26.4M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $725M | $480M | $246M | +51% |
| Net loss | $23.6M | $20.9M | $2.7M | +13% |
| Costs & expenses | $749M | $500M | $249M | +50% |
| Operating costs | $732M | $479M | $253M | +53% |
| Interest & other, net | $16.3M | $20.8M | −$4.6M | -22% |
| Income tax | $1.1M | $906K | $212K | +23% |
| Cost of revenue | $637M | $380M | $257M | +68% |
| SG&A | $73.1M | $77.6M | −$4.5M | -6% |
| Other operating costs | $21.5M | $21.3M | $197K | +0.9% |
| Operating cash sources | $49.9M | $36.7M | $13.3M | +36% |
| Depreciation & amortization | $21.5M | $23.6M | −$2.1M | -9% |
| Share-based compensation | $14.8M | $14.7M | $122K | +0.8% |
| Working capital & other | $13.6M | −$1.6M | $15.3M | — |
| Net loss absorbed | $23.6M | $20.9M | $2.7M | +13% |
| Operating cash flow | $26.4M | $15.8M | $10.6M | +67% |
Questions
How much did Evolent Health's revenue grow year over year in Q3 2026?
Evolent Health's revenue rose $246M (+51%) from $480M in Q3 2025 to $725M in Q3 2026.